Results 111 to 120 of about 14,298 (222)

A Backwards Approach to GD2 Immunofluorescence in Human Neuroblastoma Tissue Samples: From Staining to Slicing

Cells
Background: The disialoganglioside GD2, located at the plasma membrane, is selectively overexpressed in various solid tumors, where it contributes to tumor growth and the development of an aggressive tumor phenotype.
Sara Peggion, Clara Volz, Magdalena Trochimiuk, Isabelle Ariane Bley, Júlia Ramos, Konrad Reinshagen, Laia Pagerols Raluy   +6 more
doaj   +1 more source

Concurrent Treatment With Lorlatinib and Dinutuximab Beta Induced Acute Gastric Dilation in a Pediatric Patient With Neuroblastoma

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Suna Lin, Linjie Li, JiJun Chen, Zhaokun Tao, Lifeng Zhang, Junqing Mao, Jinhu Wang   +6 more
wiley   +1 more source

Anti-Neuroblastoma Activity of Gold Nanorods Bound with GD2 Monoclonal Antibody under Near-Infrared Laser Irradiation [PDF]

, 2011
High-risk neuroblastoma is one of the most common deaths in pediatric oncology. Current treatment of this disease involves a coordinated sequence of chemotherapy, surgery, and radiation.
Ching-An Peng, Chung-Hao Wang, Peng, Ching-An, Wang, Chung-Hao   +3 more
core   +1 more source

Early‐Phase Research in Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Jonathan Cunningham
wiley   +1 more source

Latin American Consensus on the Use of Anti-GD2 Monoclonal Antibody Therapy in Patients With High-Risk Neuroblastoma

JCO Global Oncology
PURPOSETo develop a Latin American expert consensus to support, guide, and accelerate the approval and equitable access to anti-GD2 immunotherapy for patients with high-risk neuroblastoma (HR-NB) in the region. Survival rates for HR-NB have improved with
Gabriela I. Villanueva, Sandra Alarcón, Diana Bonilla, Alejandra Casanovas, Mauricio Chaparro, Marcelo D. Coirini, Guido Felizzia, Diego Figueredo, Soad Fuentes-Alabi, Sima Ferman, Simone Franco, Mercedes Garcia Lombardi, Félix Gaytan Morales, Lauro J. Gregianin, Óscar González Ramella, Nathalia Halley, Camila Hashimoto, Arissa Ikeda, Scott Howard, Luis E. Juárez Villegas, Fabiana Morosini, Alberto Olaya Vargas, Vicente Odone-Filho, Nevicolino Pereira de Carvalho Filho, Catalina Peters, Veronica Pérez, Martín Pérez García, Agustina Pollono, Roy Rosado, Lourdes Romero, Haydeé del Pilar Salazar Rosales, Beatriz Silva, Victoria Sobrero, Delia P. Streitenberger, Diana Valencia, Mariana Varela, Milena Villarroel   +36 more
doaj   +1 more source

Prospects of anti-GD2 immunotherapy for retinoblastoma

Frontiers in Immunology
Retinoblastoma is the most common type of eye tumor in infants and children. Current treatments for retinoblastoma include intravenous chemotherapy, intra-arterial chemotherapy, intravitreal chemotherapy, cryotherapy, radiotherapy, and surgery.
Xinlong Zhang, Xinlong Zhang, Xinlong Zhang, Wulin You, Wulin You, Yuntao Wang, Yuntao Wang, Yuntao Wang, Rebeka Dejenie, Rebeka Dejenie, Chenhao Wang, Yan Huang, Yan Huang, Yan Huang, Jingjing Li, Jingjing Li, Jingjing Li, Jingjing Li   +17 more
openaire   +3 more sources

Chemistry and biology of tumor-associated ganglioside GD2

, 2012
Effective therapies typically target diseased tissues without significantly affecting healthy tissues. A tumor-related glycosphingolipid (GSL), such as ganglioside GD2, distinguishes neuroectoderm tumors from their healthy counterparts and is a validated
Tong, Wenyong
core  

Crucial roles of exosomes secreted from ganglioside GD3/GD2-positive glioma cells in enhancement of the malignant phenotypes and signals of GD3/GD2-negative glioma cells [PDF]

Neuroectoderm-derived tumors characteristically express gangliosides such as GD3 and GD2. Many studies have reported that gangliosides GD3/GD2 enhance malignant phenotypes of cancers.
Kambe, Mariko, Ohkawa, Yuki, Furukawa, Keiko, Mizutani, Momoka, Furukawa, Koichi, Hashimoto, Noboru, Kawamoto, Yoshiyuki, Tajima, Orie, Hasnat, Mohammad Abul, Bhuiyan, Robiul H., Yesmin, Farhana, Kaneko, Kei, Tsuchida, Akiko, Ohmi, Yuhsuke   +13 more
core   +1 more source

Combined use of niraparib enhanced the inhibitory effect of Anti-GD2 antibody on osteosarcoma cells

Discover Oncology
Purpose This study aims to investigate the effect of Niraparib in combination with an Anti-GD2 Antibody on osteosarcoma cells. Methods Scratch test was utilized to assess cell migration capacity, while the Transwell experiment was utilized to evaluate ...
Chen Wenyao, Ma Shuai, Fan Yifeng, Li Xinzhi, Que Xiangyong   +4 more
doaj   +1 more source

Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro.

PLoS ONE
Cancer immunotherapy, particularly T cell-based therapies, is considered to have strong potential for treating various types of cancer. A promising approach that has emerged is the use of γδ T cell-based strategies for cancer treatment. Neuroblastoma (NB)
Kuntida Kitidee, Sumet Amonyingcharoen, Sarinthip Preedagasamzin, Korakot Atjanasuppat, Piamsiri Sawaisorn, Pornprapa Srimorkun, Sawang Petvises, Wanpen Chaicumpa, Suparerk Borwornpinyo, Usanarat Anurathapan, Suradej Hongeng   +10 more
doaj   +1 more source